Given the higher incidence of ERBB2 mutations in breast cancer and gynecologic cancer, the analysis was re-conducted with these cancers being excluded, which showed a consistent higher rate in female patients compared to male patients (3.1% vs. 1.5%, p < 0.0001 for SNVs/indels and 2.7% vs. 2.1%, p = 0.037 for amplifications). The gene discussed is ERBB2; the disease is female reproductive organ cancer.